Skip to main content

Advertisement

SpringerLink
Log in

Clinical Utility of Biomarkers in IBD

  • Inflammatory Bowel Disease (SB Hanauer, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

There is no gold standard for the diagnosis and monitoring of inflammatory bowel diseases (IBD). Biomarkers are useful tools for the management of patients suffering from IBD. However, they should be used only when their additional information is useful for clinical decision-making. In principal, four situations during the management of an individual IBD patient can be discriminated from a clinical standpoint in which biomarkers provide useful information. First, biomarkers may be helpful when the diagnosis of IBD is established and aid in the discrimination between ulcerative colitis (UC) and Crohn’s disease (CD) is necessary. Second, biomarkers may be helpful in the prognostic evaluation of IBD severity or disease behavior and for early decisions on the best treatment. The third situation in which biomarkers are useful is the evaluation of disease activity during the disease course, for monitoring and for guidance of ongoing treatment. Finally, the fourth typical situation when biomarkers are of value is after surgery to predict or diagnose a relapse of the disease. From a clinical point of view, it may be more useful to discuss specific biomarkers and their individual value and impact in these four prototypic situations than to sum up advantages and disadvantages for each biomarker isolated from the clinical situation. Therefore, this overview is structured in chapters reflecting those four typical situations during the disease course of IBD patents to critically evaluate the potential and value of each of the biomarkers in the specific situation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–6.

    PubMed Central  PubMed  Google Scholar 

  2. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.

    Google Scholar 

  3. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Exp Rev Gastroenterol Hepatol. 2014;8(2):197–210.

    CAS  Google Scholar 

  4. Dubinsky MC. Clinical perspectives in Crohn’s disease. Serologic and prognostic biomarkers: who, when, and how? Rev Gastroenterol Disord. 2007;7 Suppl 2:S3–7.

    PubMed  Google Scholar 

  5. Li X, Conklin L, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008;14(33):5115–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Barahona-Garrido J, Sarti HM, Barahona-Garrido MK, Hernandez-Calleros J, Coss-Adame E, Garcia-Saenz SM, et al. Serological markers in inflammatory bowel disease: a review of their clinical utility. Rev Gastroenterol Mex. 2009;74(3):230–7.

    CAS  PubMed  Google Scholar 

  7. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394–403.

    PubMed Central  PubMed  Google Scholar 

  8. Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm Bowel Dis. 2004;10(3):240–4.

    PubMed  Google Scholar 

  9. Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. 2009;56(89):162–6.

    PubMed  Google Scholar 

  10. Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103(3):665–81.

    CAS  PubMed  Google Scholar 

  11. Papp M, Norman GL, Altorjay I, Lakatos PL. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13(14):2028–36.

    PubMed Central  PubMed  Google Scholar 

  12. Plevy S. Do serological markers and cytokines determine the indeterminate? J Clin Gastroenterol. 2004;38(5 Suppl 1):S51–6.

    PubMed  Google Scholar 

  13. Tung CC, Wong JM, Lee WC, Liu HH, Chang CH, Chang MC, et al. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn’s disease. J Gastroenterol Hepatol. 2014;29(4):723–9. An attempt to find biomarkers for the prediction of disease courses in Crohn’s disease illustrating the associated problems.

    CAS  PubMed  Google Scholar 

  14. Eser A, Papay P, Primas C, Pernicka E, Harrer M, Dejaco C, et al. The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn’s disease. Aliment Pharmacol Ther. 2012;35(2):292–9.

    CAS  PubMed  Google Scholar 

  15. Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104(7):1745–53.

    CAS  PubMed  Google Scholar 

  16. Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, et al. Low Mannan-binding lectin serum levels are associated with complicated Crohn’s disease and reactivity to oligomannan (ASCA). Am J Gastroenterol. 2009;104(10):2508–16.

    CAS  PubMed  Google Scholar 

  17. Schaffer T, Muller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn’s patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis. 2007;13(11):1339–46.

    PubMed  Google Scholar 

  18. Mokrowiecka A, Gasiorowska A, Malecka-Panas E. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology. 2007;54(77):1443–8.

    CAS  PubMed  Google Scholar 

  19. Seibold F. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Gut. 2005;54(9):1212–3.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Dubinsky MC. What is the role of serological markers in the diagnosis of IBD? Inflamm Bowel Dis. 2008;14 Suppl 2:S185–6.

    PubMed  Google Scholar 

  21. Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, Papadakis KA, et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn’s disease. Inflamm Bowel Dis. 2006;12(12):1122–30.

    PubMed  Google Scholar 

  22. Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55(11):1667–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn’s disease. Gastroenterology. 2006;130(4):1078–85.

    CAS  PubMed  Google Scholar 

  24. Wei B, Dalwadi H, Gordon LK, Landers C, Bruckner D, Targan SR, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun. 2001;69(10):6044–54.

    CAS  PubMed Central  PubMed  Google Scholar 

  25. Shen C, Landers CJ, Derkowski C, Elson CO, Targan SR. Enhanced CBir1-specific innate and adaptive immune responses in Crohn’s disease. Inflamm Bowel Dis. 2008;14(12):1641–51.

    PubMed Central  PubMed  Google Scholar 

  26. Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas E, Mei L, Papadakis KA, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6(5):561–8.

    PubMed Central  PubMed  Google Scholar 

  27. Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm Bowel Dis. 2007;13(5):524–30.

    PubMed  Google Scholar 

  28. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128(7):2020–8.

    CAS  PubMed  Google Scholar 

  29. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16(8):1367–75.

    PubMed  Google Scholar 

  30. Deusch K, Oberstadt K, Schaedel W, Weber M, Classen M. p-ANCA as a diagnostic marker in ulcerative colitis. Adv Exp Med Biol. 1993;336:527–31.

    CAS  PubMed  Google Scholar 

  31. Rump JA, Worner I, Roth M, Scholmerich J, Hansch M, Peter HH. p-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity and therapy. Adv Exp Med Biol. 1993;336:507–13.

    CAS  PubMed  Google Scholar 

  32. Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003;35(12):862–8.

    CAS  PubMed  Google Scholar 

  33. Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, et al. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss cohort. Inflamm Bowel Dis. 2009;15(9):1358–67.

    PubMed Central  PubMed  Google Scholar 

  34. Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001;126(1):37–46.

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Franks I. IBD: CRP is a good long-term biomarker. Nat Rev Gastroenterol Hepatol. 2011;8(7):359.

    Google Scholar 

  36. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–9.

    PubMed  Google Scholar 

  37. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9.

    CAS  PubMed  Google Scholar 

  38. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32–9.

    PubMed  Google Scholar 

  39. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol. 1997;9(10):939–44.

    CAS  PubMed  Google Scholar 

  40. Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn’s disease. J Pediatr Gastroenterol Nutr. 1996;23(2):164–71.

    CAS  PubMed  Google Scholar 

  41. Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(1):74–80. Excellent review on the diagnostic value of calprotectin in inflammatory bowel disease.

    CAS  PubMed  Google Scholar 

  42. Mooiweer E, Severs M, Schipper ME, Fidder HH, Siersema PD, Laheij RJ, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9(1):50–5. Intersting study showing the value of calprotectin in monitoring IBD patients: Low calprotectin levels in IBD patients predict a stable remission during follow-up.

    PubMed  Google Scholar 

  43. Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015;9(1):1–3.

    PubMed  Google Scholar 

  44. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Color Dis. 2014;29(4):485–91. Another study showing the value of calprotectin for monitoring the course of inflammation in IBD patients: Calprotectin showed a higher sensitivity and specificity than lactoferrin for predicting a relapse in UC patients. Calprotectin level predicted a relapse in patients with quiescent UC.

    Google Scholar 

  45. Yamamoto T. Letter: faecal calprotectin and lactoferrin—accurate biomarkers in post-operative Crohn’s disease? Aliment Pharmacol Ther. 2014;40(3):321.

    CAS  PubMed  Google Scholar 

  46. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19(2):332–41. Important study showing that calprotectin levels are a surrogate marker for mucosal inflammation as they correlated better with endoscopic disease activity than clinical activity, CRP, platelets, hemoglobin, and blood leukocyte counts in CD patients.

    PubMed  Google Scholar 

  47. Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, et al. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis. 2013;7(8):670–7.

    PubMed  Google Scholar 

  48. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851–8.

    PubMed  Google Scholar 

  49. Burri E, Beglinger C. IBD: faecal calprotectin testing—the need for better standardization. Nat Rev Gastroenterol Hepatol. 2014;11(10):583–4.

    PubMed  Google Scholar 

  50. Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Letter: faecal calprotectin and lactoferrin—accurate biomarkers in post-operative Crohn’s disease—authors’ reply. Letter: biologic therapies are effective for prevention of post-operative Crohn’s disease recurrence—authors’ reply. Aliment Pharmacol Ther. 2014;40(3):323.

    CAS  PubMed  Google Scholar 

  51. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: a prospective pilot study. U Eur Gastroenterol J. 2013;1(5):368–74.

    Google Scholar 

  52. Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn’s disease in African Americans. Am J Gastroenterol. 2010;105(2):378–86.

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Marrakchi R, Bougatef K, Moussa A, Ouerhani S, Khodjet-el-Khil H, Messai Y, et al. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn’s disease in Tunisian population. Inflamm Res. 2009;58(4):218–23.

    CAS  PubMed  Google Scholar 

  54. Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, et al. Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn’s disease patients: a project of the European Collaborative Study Group on inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(7):874–81.

    PubMed  Google Scholar 

  55. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123(3):679–88.

    CAS  PubMed  Google Scholar 

  56. Carvalho AT, Esberard BC, Froes RS, Rapozo DC, Grinman AB, Simao TA, et al. Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. World J Gastroenterol. 2014;20(12):3327–34.

    PubMed Central  PubMed  Google Scholar 

  57. Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010;16(25):3187–95.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4(1):44–9.

    CAS  PubMed  Google Scholar 

  59. Linssen J, Aderhold S, Nierhaus A, Frings D, Kaltschmidt C, Zanker K. Automation and validation of a rapid method to assess neutrophil and monocyte activation by routine fluorescence flow cytometry in vitro. Cytometry B Clin Cytom. 2008;74(5):295–309.

    CAS  PubMed  Google Scholar 

  60. Marafini I, Di Sabatino A, Zorzi F, Monteleone I, Sedda S, Cupi ML, et al. Serum regenerating islet-derived 3-alpha is a biomarker of mucosal enteropathies. Aliment Pharmacol Ther. 2014;40(8):974–81.

    CAS  PubMed  Google Scholar 

  61. Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49(8):942–9. Serum levels of Chromogranin A were found to be a reliable marker of disease activity in IBD patients and especially in those who received biologic therapy. No comparison to calprotectin was performed.

    CAS  PubMed  Google Scholar 

  62. Kovacs M, Muller KE, Papp M, Lakatos PL, Csondes M, Veres G. New serological markers in pediatric patients with inflammatory bowel disease. World J Gastroenterol. 2014;20(17):4873–82.

    PubMed Central  PubMed  Google Scholar 

  63. Voiosu T, Balanescu P, Bengus A, Voiosu A, Baicus CR, Barbu M, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab. 2014;60(3):505–10. Endocan is a marker of angiogenesis. In a group of 33 consecutive IBD patients from an observational cohort study endocan levels were significantly higher in the IBD group as compared to healthy controls, however, there was no correlation between endocan levels and disease activity.

    CAS  PubMed  Google Scholar 

  64. Schaffer T, Schoepfer AM, Seibold F, Swiss IBDCSG. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn’s disease activity. J Crohns Colitis. 2014;8(9):1125–32. Ficolin, another serum protein, is not superior as compared to calprotectin in the monitoring of IBD patients.

    PubMed  Google Scholar 

  65. Kofla-Dlubacz A, Matusiewicz M, Krzesiek E, Noga L, Iwanczak B. Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children. Adv Clin Exp Med : Off Organ Wroclaw Med Univ. 2014;23(1):103–10.

    Google Scholar 

  66. Morisaki T, Takeshima F, Fukuda H, Matsushima K, Akazawa Y, Yamaguchi N, et al. High serum vaspin concentrations in patients with ulcerative colitis. Dig Dis Sci. 2014;59(2):315–21.

    CAS  PubMed  Google Scholar 

  67. Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD. Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis. 2014;73(10):1873–9.

    CAS  PubMed  Google Scholar 

  68. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744–53. quiz 1754.

    PubMed  Google Scholar 

  69. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496–505.

    PubMed  Google Scholar 

  70. Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(2):199–205.

    PubMed Central  PubMed  Google Scholar 

  71. Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40(7):547–53.

    PubMed  Google Scholar 

  72. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49(6 Pt 1):861–7.

    CAS  PubMed  Google Scholar 

  73. Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol. 2014;49(12):1419–24.

    CAS  PubMed  Google Scholar 

  74. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–24. The title nicely relfects the important meassage: Fecal calprotectin can be clinically used as a surrogate marker for endoscopic lesions in IBD avoiding some endoscopies during monitoring of patients.

    PubMed  Google Scholar 

  75. Kennedy NA, Clark A, Walkden A, Chang JC, Fasci-Spurio F, Muscat M, et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years. J Crohns Colitis. 2015;9(1):41–9.

    PubMed  Google Scholar 

  76. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524–34.

    PubMed  Google Scholar 

  77. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.

    PubMed Central  PubMed  Google Scholar 

  78. Easton JA, Hardwicke J, Whitehead PH. The estimation of two alpha(1) glycoproteins (orosomucoid and another alpha(1) acid glycoprotein) in health and disease. J Clin Pathol. 1962;15(6):585–90.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol. 1997;32(9):933–41.

    CAS  PubMed  Google Scholar 

  80. Shah A, Morgan G, Rose JD, Fifield R, Rhodes J. Platelet number and size in relation to serum orosomucoid concentration in Crohn’s disease. Med Lab Sci. 1989;46(1):79–80.

    CAS  PubMed  Google Scholar 

  81. Kruis W, Fateh-Mogadam A, Sandel P. Serum levels of beta 2-microglobulin: a new marker of activity in Crohn’s disease. N Engl J Med. 1979;301(24):1348.

    CAS  PubMed  Google Scholar 

  82. Manicourt DH, Orloff S. Serum levels of beta 2-microglobulin in Crohn’s disease. N Engl J Med. 1980;302(12):696.

    CAS  PubMed  Google Scholar 

  83. Ricci G, D’Ambrosi A, Resca D, Masotti M, Alvisi V. Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother. 1995;49(5):259–62.

    CAS  PubMed  Google Scholar 

  84. Yilmaz B, Koklu S, Yuksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20(31):10916–20.

    PubMed Central  PubMed  Google Scholar 

  85. Chambers RE, Stross P, Barry RE, Whicher JT. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur J Clin Invest. 1987;17(5):460–7.

    CAS  PubMed  Google Scholar 

  86. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet. 1982;2(8292):231–4.

    PubMed  Google Scholar 

  87. Lopes S, Figueiredo P, Portela F, Freire P, Almeida N, Lerias C, et al. Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. Inflamm Bowel Dis. 2010;16(10):1663–8.

    PubMed  Google Scholar 

  88. Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol. 2009;62(3):201–5.

    CAS  PubMed  Google Scholar 

  89. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (ANTI-SACCHAROMYCES cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120(4):827–33.

    CAS  PubMed  Google Scholar 

  90. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101(10):2410–22.

    CAS  PubMed  Google Scholar 

  91. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96(3):730–4.

    CAS  PubMed  Google Scholar 

  92. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122(5):1242–7.

    PubMed  Google Scholar 

  93. Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Exp Rev Gastroenterol Hepatol. 2007;1(2):265–74.

    CAS  Google Scholar 

  94. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006;131(2):366–78.

    CAS  PubMed  Google Scholar 

  95. Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101(3):645–52.

    PubMed  Google Scholar 

  96. Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2(2):139–46.

    CAS  PubMed  Google Scholar 

  97. Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn’s disease. Inflamm Bowel Dis. 2010;16(8):1279–85.

    PubMed  Google Scholar 

  98. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101(2):360–7.

    PubMed Central  PubMed  Google Scholar 

  99. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99(12):2376–84.

    PubMed  Google Scholar 

  100. Annese V, Lombardi G, Perri F, D’Inca R, Ardizzone S, Riegler G, et al. Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol. 2005;100(1):84–92.

    CAS  PubMed  Google Scholar 

  101. Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, et al. NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology. 2007;132(2):576–86.

    CAS  PubMed  Google Scholar 

  102. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12(4):351–9.

    CAS  PubMed  Google Scholar 

  103. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–31.

    CAS  PubMed Central  PubMed  Google Scholar 

  104. Molander P, Farkkila M, Ristimaki A, Salminen K, Kemppainen H, Blomster T, et al. Does fecal calprotectin predict short-term relapse after stopping tnfalpha-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33–40. Fecal calprotectin was found to increase and remain elevated before clinical or endoscopic relapse in patients that stop anti-TNF therapy. The authors subsequently suggest “that it can be used as a surrogate marker for predicting and identifying patients requiring close follow-up in clinical practice”.

    PubMed  Google Scholar 

  105. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22.

    CAS  PubMed  Google Scholar 

  106. Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887–1893 e1883. The first study showing that a clinical intervention (increase of 5-ASA) based on calprotectin levels during monitoring can be beneficial for the long-term outcome.

    CAS  PubMed  Google Scholar 

  107. Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydstrom B, et al. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease—a comparison with findings at ileocolonoscopy. J Crohns Colitis. 2014;8(8):789–95. Calprotectin predicts postoperative relaps and may be used in the postoperative setting to monitor IBD patients.

    PubMed  Google Scholar 

  108. Yamamoto T, Kotze PG. Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn’s disease? J Crohns Colitis. 2013;7(12):e712.

    PubMed  Google Scholar 

  109. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, Ruiz A, Rodriguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis. 2013;7(12):e641–51. Rapids tests may have the same potential as compared to standard ELISAs.

    PubMed  Google Scholar 

  110. Seibold F, Schoepfer AM. Can fecal calprotectin or lactoferrin identify postoperative recurrence in Crohn’s disease? Inflamm Bowel Dis. 2010;16(10):1814–5.

    PubMed  Google Scholar 

  111. Lamb CA, Mohiuddin MK, Gicquel J, Neely D, Bergin FG, Hanson JM, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96(6):663–74.

    CAS  PubMed  Google Scholar 

  112. Wright E, De Cruz P, Hamilton A, Ritchie K, Krejany S, Leach S, et al. Faecal calprotectin helps determine the need for post-operative colonoscopy in Crohn’s disease. Prospective longitudinal endoscopic validation. Results from the POCER study. UEG J. 2013;1 Suppl 1:A35.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Gerhard Rogler reports personal fees from Abbot, Abbvie, Augurix, Boehringer, Calypso, FALK, Ferring, Fisher, Genentech, Essex/MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; grants from Abbot, Abbvie, Ardeypharm, Augurix, Calypso, Essex/MSD, FALK, Flamentera, Novartis, Roche, Takeda, Tillots, UCB and Zeller; and personal fees from Astra Zeneca, Abbott, Abbvie, FALK, MSD, Phadia, Tillots, UCB, and Vifor, outside the submitted work.

Luc Biedermann declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland

    Gerhard Rogler & Luc Biedermann

Authors
  1. Gerhard Rogler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luc Biedermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhard Rogler.

Additional information

This article is part of the Topical Collection on Inflammatory Bowel Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rogler, G., Biedermann, L. Clinical Utility of Biomarkers in IBD. Curr Gastroenterol Rep 17, 26 (2015). https://doi.org/10.1007/s11894-015-0449-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-015-0449-x

Keywords

Search

Navigation